Results 141 to 150 of about 2,218,427 (310)

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Drug development and registration: Challenges and opportunities in ovarian cancer [PDF]

, 2017
S. Percy Ivy, Elise C. Kohn
openalex   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Pediatric Drug Development

Clinical Therapeutics, 2014
openaire   +3 more sources

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source

Advancing Outcome Measures for the New Era of Drug Development in Cystic Fibrosis

, 2007
Nicole Mayer-Hamblett, Bonnie W. Ramsey, R. A. Kronmal   +2 more
openalex   +1 more source

Colorectal cancer‐derived FGF19 is a metabolically active serum biomarker that exerts enteroendocrine effects on mouse liver

Molecular Oncology, EarlyView.
Meta‐transcriptome analysis identified FGF19 as a peptide enteroendocrine hormone associated with colorectal cancer prognosis. In vivo xenograft models showed release of FGF19 into the blood at levels that correlated with tumor volumes. Tumoral‐FGF19 altered murine liver metabolism through FGFR4, thereby reducing bile acid synthesis and increasing ...
Jordan M. Beardsley, Michael W. Rohr, Joseph A. Goode, Sai Preethi Nakkina, Jignesh G. Parikh, Deborah A. Altomare   +5 more
wiley   +1 more source

Translational molecular imaging and drug development in multiple sclerosis. [PDF]

Theranostics
Tay D, Ahmed H, Dawoud A, Salam M, Gobbi L, Grether U, Edelmann MR, Wittwer MB, Collin L, Atz K, Keaney J, Giroud M, Rossi A, Gennari AG, Pagano G, Parrot NJ, Barakovic M, Rominger A, Gebhard C, Ametamey SM, Saindane AM, Liang SH, Haider A.   +22 more
europepmc   +1 more source

NLRP3 Inflammasome Inhibitors for Antiepileptogenic Drug Discovery and Development

Inamul Haque, Pritam Thapa, Douglas M. Burns, Jianping Zhou, Mukut Sharma, Ram Sharma, Vikas Singh   +6 more
openalex   +2 more sources

Nitrite in Pharmaceutical Manufacturing Water: Development of an Ultra-Sensitive Analytical Method, Typical Data, and Discussion of Potential Nitrosamine Formation in Drug Substance and Drug Product from Water [PDF]

A. B. Suresh Kumar, Debasis Dey, T. S. Balaji, Haridoss Karthik, K. Sathishkumar, Paul McDaid, Brian Fitzpatrick, Atul Awasthi, Simon Davies, Olivier Dirat   +9 more
openalex   +1 more source